Mechanisms of Refractory Hypertension (Reserpine)
Primary Purpose
Refractory Hypertension
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Reserpine
Sponsored by

About this trial
This is an interventional treatment trial for Refractory Hypertension focused on measuring hypertension, sympathetic tone, resperpine
Eligibility Criteria
Inclusion Criteria:
- adult with refractory hypertension defined as uncontrolled office blood pressure with use of 5 or more hypertensive agents, including a thiazide diuretic and spironolactone
Exclusion Criteria:
- congestive heart failure (EF 40%)
- chronic kidney disease (GFR <40 ml/min/1.73 mm)
- stroke and/or myocardial infarction or acute CHF exacerbation within last 3 months
- ongoing depression
- active peptic ulcer disease
- bradycardia <50 beats per minute
- 2nd or 3rd degree heart block
- known intolerance of reserpine
- use of digoxin or tricycle antidepressants
Sites / Locations
- UAB
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Reserpine
Arm Description
Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.
Outcomes
Primary Outcome Measures
Change Ambulatory Systolic Blood Pressure
Twenty-four hour ambulatory systolic blood pressure
Secondary Outcome Measures
Full Information
NCT ID
NCT03223272
First Posted
July 17, 2017
Last Updated
November 2, 2021
Sponsor
University of Alabama at Birmingham
1. Study Identification
Unique Protocol Identification Number
NCT03223272
Brief Title
Mechanisms of Refractory Hypertension (Reserpine)
Official Title
Mechanisms of Refractory Hypertension (Reserpine)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
July 23, 2015 (Actual)
Primary Completion Date
January 31, 2020 (Actual)
Study Completion Date
January 31, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.
Detailed Description
Patients with refractory hypertension, defined as uncontrolled office blood pressure despite use of 5 or more antihypertensive agents, including a thiazide diuretic and spironolactone. After withdrawal from other centrally-acting agents if needed, enrolled patients will be randomized to open-label reserpine 0.1 mg daily for 4 weeks. Twenty-four hour ambulatory blood pressure monitoring will be done at baseline, after the initial 4-week treatment period. All other antihypertensive medications will remain unchanged during the 4-week treatment period. The primary endpoint will be change in 24-hr ambulatory systolic blood pressure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Refractory Hypertension
Keywords
hypertension, sympathetic tone, resperpine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Open-label, dose titration study
Masking
None (Open Label)
Allocation
N/A
Enrollment
7 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Reserpine
Arm Type
Experimental
Arm Description
Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.
Intervention Type
Drug
Intervention Name(s)
Reserpine
Intervention Description
Open label reserpine 0.1 mg pill orally
Primary Outcome Measure Information:
Title
Change Ambulatory Systolic Blood Pressure
Description
Twenty-four hour ambulatory systolic blood pressure
Time Frame
Baseline and 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
- adult with refractory hypertension defined as uncontrolled office blood pressure with use of 5 or more hypertensive agents, including a thiazide diuretic and spironolactone
Exclusion Criteria:
congestive heart failure (EF 40%)
chronic kidney disease (GFR <40 ml/min/1.73 mm)
stroke and/or myocardial infarction or acute CHF exacerbation within last 3 months
ongoing depression
active peptic ulcer disease
bradycardia <50 beats per minute
2nd or 3rd degree heart block
known intolerance of reserpine
use of digoxin or tricycle antidepressants
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David A Calhoun, MD
Organizational Affiliation
University of Alabama at Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
UAB
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35292
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
One year after study completion, de-identified subject demographic data and primary outcome data will be available by request.
IPD Sharing Time Frame
One year after study completion
IPD Sharing Access Criteria
By request.
Learn more about this trial
Mechanisms of Refractory Hypertension (Reserpine)
We'll reach out to this number within 24 hrs